| NCT ID | NCT01224886 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Lausanne |
| Condition | Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2010-10 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2010-10 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Insulin resistance is a crucial factor for the development of type 2 diabetes and a major health problem for older adults. It is the principal mechanism by which obesity is considered to increase the risk for type 2 diabetes and is a key feature of the metabolic syndrome. The elevated prevalence of obesity and type 2 diabetes in the older population has important consequences on the morbidity and mortality as well as on the economic burden on society. Controversy currently exists as to whether or not aging contributes to insulin resistance. Many potential factors confound the association between aging and insulin resistance, including obesity and physical inactivity. Ectopic lipid depositions, defined as an excess accumulation of triglycerides in non adipose tissues such as in the liver (intrahepatic lipids) and within the muscle fibers (intramyocellular lipids), are positively associated with obesity and insulin resistance. Furthermore, the accumulation of intracellular lipids is often cited as being a key determinant in the underlying mechanisms of insulin resistance. In addition of playing an important role in obesity and type 2 diabetes, these ectopic fat depositions are also observed in common conditions such as aging and physical inactivity. The intervention trial will test in skeletal muscle, liver and heart of sedentary obese volunteers, normal weight volunteers and masters athletes, the overall hypotheses that exercise improvement of fat oxidation capacity and/or decrease of damaging fat metabolites is a primary factor that predicts the improvement in insulin resistance.
Eligibility Criteria
Inclusion Criteria: * Age 60-80 * Sedentary or highly trained * BMI 18-40 * Non-Smoker * Normal glucose tolerance or impaired glucose tolerance * Willingness to comply with the protocol Exclusion Criteria: * Contraindication to moderate exercise or clinical conditions precluding from joining an exercise program, such as clinically significant cardiovascular disease, peripheral vascular disease, uncontrolled hypertension, neurological or orthopedic disease * Recent weight loss or weight gain * Known diabetes * Known drugs to affect glucose homeostasis such as nicotinic acid, glucocorticoids * Severe anemia or lipid disturbances, hepatic or renal disease * Recent history of cancer * Hypothyroidism * Recent hormone replacement therapy * Known allergy to lidocaine or other local anesthetic * Positive stress test * Active alcohol or substance abuse
Contact & Investigator
Francesca Amati, MD,PhD
PRINCIPAL INVESTIGATOR
University of Lausanne
Frequently Asked Questions
Who can join the NCT01224886 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 80 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01224886 currently recruiting?
Yes, NCT01224886 is actively recruiting participants. Contact the research team at francesca.amati@unil.ch for enrollment information.
Where is the NCT01224886 trial being conducted?
This trial is being conducted at Bern, Switzerland, Lausanne, Switzerland.
Who is sponsoring the NCT01224886 clinical trial?
NCT01224886 is sponsored by University of Lausanne. The principal investigator is Francesca Amati, MD,PhD at University of Lausanne. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.